|
#Unite2FightCorona #IndiaFightsCorona
Press Information Bureau
Ministry of Information & Broadcasting
Government of India
*****
India’s Cumulative COVID-19 Vaccination Coverage exceeds 199.47 Cr
Over 3.78 Cr 1st dose vaccines administered for age group 12-14 years
India’s Active caseload currently stands at 1,39,073
20,038 new cases reported in the last 24 hours
Recovery Rate currently stands at 98.48%
Weekly Positivity Rate is presently at 4.30%
India’s COVID-19 vaccination coverage has exceeded 199.47 Cr (1,99,47,34,994) as per provisional reports till 7 am today. This has been achieved through 2,62,39,248 sessions.
COVID-19 vaccination for the age group 12-14 years was started on 16 March, 2022. So far, more than 3.78 Cr (3,78,17,085) adolescents have been administered with the first dose of COVID-19 vaccine. Similarly, the COVID-19 precaution dose administration for age group 18-59 years also started from 10th April, 2022 onwards.
The break-up of the cumulative figure as per the provisional report till 7 am today include:
Cumulative Vaccine Dose Coverage | ||
HCWs | 1st Dose | 1,04,10,122 |
2nd Dose | 1,00,77,923 | |
Precaution Dose | 59,76,465 | |
FLWs | 1st Dose | 1,84,27,018 |
2nd Dose | 1,76,48,924 | |
Precaution Dose | 1,13,40,481 | |
Age Group 12-14 years | 1st Dose | 3,78,17,085 |
2nd Dose | 2,58,85,543 | |
Age Group 15-18 years | 1st Dose | 6,07,95,643 |
2nd Dose | 4,99,66,327 | |
Age Group 18-44 years | 1st Dose | 55,88,05,216 |
2nd Dose | 50,53,78,624 | |
Precaution Dose | 45,26,422 | |
Age Group 45-59 years | 1st Dose | 20,35,53,440 |
2nd Dose | 19,44,40,660 | |
Precaution Dose | 32,84,723 | |
Over 60 years | 1st Dose | 12,73,48,903 |
2nd Dose | 12,14,98,144 | |
Precaution Dose | 2,75,53,331 | |
Precaution Dose | 5,26,81,422 | |
Total | 1,99,47,34,994 |
India’s Active Caseload currently stands at 1,39,073. Active cases now constitute 0.32% of the country’s total Positive Cases.
Consequently, India’s recovery rate stands at 98.48%. 16,994 patients have recovered in the last 24 hours and the cumulative tally of recovered patients (since the beginning of the pandemic) is now at 4,30,45,350.
20,038 new cases were reported in the last 24 hours.
The last 24 hours saw a total of 4,50,820 COVID-19 tests being conducted. India has so far conducted over 86.86 Cr (86,86,15,168) cumulative tests.
Weekly Positivity Rate in the country currently stands at 4.30% and the Daily Positivity rate is reported to be 4.44%.
https://www.pib.gov.in/PressReleasePage.aspx?PRID=1841613
Update on COVID-19 Vaccine Availability in States/UTs
More than 193.53 Crore vaccine doses provided to States/UTs
More than 9.70 Crore balance and unutilized vaccine doses still available with States/UTs
The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country. The nationwide COVID 19 vaccination started on 16th January 2021. The new phase of universalization of COVID-19 vaccination commenced from 21st June 2021. The vaccination drive has been ramped up through availability of more vaccines, advance visibility of vaccine availability to States and UTs for enabling better planning by them, and streamlining the vaccine supply chain.
As part of the nationwide vaccination drive, Government of India has been supporting the States and UTs by providing them COVID Vaccines free of cost. In the new phase of the universalization of the COVID19 vaccination drive, the Union Government will procure and supply (free of cost) 75% of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.
VACCINE DOSES |
(As on 15th July 2022) |
SUPPLIED |
1,93,53,58,865 |
BALANCE AVAILABLE
|
9,70,62,185 |
More than 193.53 crore (1,93,53,58,865) vaccine doses have been provided to States/UTs so far through Govt. of India (free of cost channel) and through direct state procurement category.
More than 9.70 Cr (9,70,62,185) balance and unutilized COVID Vaccine doses are still available with the States/UTs to be administered.
https://www.pib.gov.in/PressReleasePage.aspx?PRID=1841608
Covaxin can help in controlling the virus load of SARS-CoV-2 & its variants, reducing disease severity: Study
Scientists have found that Covaxin, which is an inactivated whole-virion vaccine, induces robust immune memory to SARS-CoV-2 and variants of concern that persist for at least 6 months after vaccination and induces memory T cells that can respond robustly against the variants. This may help in controlling the virus load and thus, reduce the disease severity.
BBV152/Covaxin vaccine is based on an Asp614Gly variant and formulated with a toll-like receptor (TLR) 7/8 agonist molecule (imidazoquinolin) adsorbed to alum. It was the first alum-imidazoquinolin adjuvanted vaccine produced in India and received emergency use authorization from WHO for use in a large population.
For Details:- https://pib.gov.in/PressReleasePage.aspx?PRID=1841775
Tweet Links